Management of Metastatic Pancreatic Adenocarcinoma Review uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Disease Management
  • Pancreatic Neoplasms

abstract

  • Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and clinically challenging malignancies to treat, with an estimated 5-year survival rate of approximately 7%. At the time of initial presentation, a majority of patients have metastatic disease. The median overall survival in these patients with good performance status is 8.5 to 11.1¬†months and in patients with significantly impaired performance status, even less. Strategies to integrate novel agents with traditional cytotoxic therapies are under investigation and hold promise for improving outcomes in patients with metastatic PDAC. This article focuses on the current management options and novel therapeutics for metastatic PDAC.

publication date

  • December 2016

Research

keywords

  • Review

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.suc.2016.07.011

PubMed ID

  • 27865284

Additional Document Info

start page

  • 1391

end page

  • 1414

volume

  • 96

number

  • 6